Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...
Melvin L.K. Chua, FRCR, PhD, FASCO, highlights data validating the performance of the ArteraAI Prostate test in an Asian cohort of patients with prostate cancer. “Nivolumab, combined with standard of ...
While no resource is perfect, it is worthwhile to familiarize yourself with some contemporary methodology and predictive tools to help determine life expectancy in localized prostate cancer patients.
An expert discusses how his diagnostic treatment workflow for a new patient with benign prostatic hyperplasia (BPH) progresses from initial α-blocker therapy through noninvasive systematic testing ...
CAN-2409 plus valacyclovir significantly improved disease-free survival compared with placebo plus valacyclovir. Phase 3 data from the PrTK03 trial (NCT01436968) were recently presented at the ...
Findings showed that although most applicants emphasized work ethic and interpersonal skills, these attributes were not predictive of receiving an interview invitation. In this video, Sevann Helo, MD, ...
CAN-2409 plus valacyclovir significantly improved DFS in localized intermediate- to high-risk prostate cancer, showing a 30% improvement over standard care. The treatment enhanced CD8+ T cell response ...
The Virtuoso Surgical Robotic System received FDA breakthrough designation for bladder lesion removal, enabling expedited development and review processes. En bloc resection improves cancer staging ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback